Clinical trialPhase 2Terminated

Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer

A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) With or Without T-ChOS as Adjuvant Therapy in Patients With Surgically Resected Pancreatic Cancer.

NCT02767752 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Stopped earlyPoor accrual and change of SOC (FOLFIRINOX in adjuvant setting) (Enrollment)
Phase: Phase 2
Status: Terminated
Study type: Interventional
Start: November 2016
Expected end: July 2018
Enrollment: 21 participants
Sites: 1
Primary outcomes: Disease-free survival (DFS)
Sponsor: Other
Results posted: No
Last update: 10 July 2018

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a single center, randomized, double-blind, placebo-controlled phase II trial that will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 months in patients with surgically resected pancreatic adenocarcinoma.

Papers 1

Registry-listed results paperA Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therap… DOI 10.3390/pharmaceutics14030509 ↗

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.